Revised forecast
Fiscal year ending March 2027 · Full yearThe bar length represents the relative magnitude of change, based on the item that changed the most in this document.
No specific reasons for the revision to the earnings forecast for the fiscal year ending March 2027 were disclosed. For the fiscal year ended March 2026, the company cited lower revenue in the biological examination equipment and patient monitoring systems segments, along with growth in its rental business for home healthcare.
Directors' retirement benefits: ¥3 million; loss on disposal of fixed assets: ¥1 million; impairment loss: ¥137 million; valuation loss on investment securities: ¥343 million; building demolition costs: ¥84 million; other: ¥1 million; total extraordinary losses: ¥571 million
| Item | Details |
|---|---|
| Net Sales | Not disclosed → ¥142,000 million（+1.6%） |
| Operating profit | Not disclosed → ¥25,500 million（-4.2%） |
| Ordinary income | Not disclosed → ¥25,500 million（-6.7%） |
| Profit attributable to owners of the parent | Not disclosed → ¥17,700 million（-5.8%） |
| Net income per share | Not disclosed → 655.17 yen and sen（-4.1%） |
| Fiscal Period Covered | Fiscal year ending March 2027 |
| Period Covered | Full year |
| Previous-period results | Revenue: ¥139,697 million; operating income: ¥26,608 million; ordinary income: ¥27,341 million; net income attributable to owners of the parent: ¥18,790 million; earnings per share: ¥683.41 (fiscal year ended March 2026) |
| Reason for the revision | No specific reasons for the revision to the earnings forecast for the fiscal year ending March 2027 were disclosed. For the fiscal year ended March 2026, the company cited lower revenue in the biological examination equipment and patient monitoring systems segments, along with growth in its rental business for home healthcare. |
| Details and amount of extraordinary loss | Directors' retirement benefits: ¥3 million; loss on disposal of fixed assets: ¥1 million; impairment loss: ¥137 million; valuation loss on investment securities: ¥343 million; building demolition costs: ¥84 million; other: ¥1 million; total extraordinary losses: ¥571 million |
| Dividend forecast revision | The forecast for the fiscal year ending March 2027 is ¥115 per share for the second-quarter-end dividend, ¥115 per share for the year-end dividend and ¥230 per share for the full year. Whether the dividend forecast was revised was not disclosed. |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (1)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.For the fiscal year ended March 2026, the company cited lower revenue in the biological examination equipment and patient monitoring systems segments, along with growth in the therapeutic equipment segment, including its rental business for home healthcare. For the fiscal year ending March 2027, no specific reasons were provided for the year-on-year changes in the earnings forecast.